Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply

Steven R. Ytterberg; Deepak L. Bhatt; Carol A. Connell

doi:10.1056/NEJMc2202778

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply

Steven R. Ytterberg, Deepak L. Bhatt, Carol A. Connell

Rheumatology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1768
Number of pages	1
Journal	The New England journal of medicine
Volume	386
Issue number	18
DOIs	https://doi.org/10.1056/NEJMc2202778
State	Published - May 5 2022

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMc2202778

Cite this

@article{a8139723e0914cf09ea226a31d0593c6,

title = "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply",

author = "Ytterberg, {Steven R.} and Bhatt, {Deepak L.} and Connell, {Carol A.}",

year = "2022",

month = may,

day = "5",

doi = "10.1056/NEJMc2202778",

language = "English (US)",

volume = "386",

pages = "1768",

journal = "New England Journal of Medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

number = "18",

}

TY - JOUR

T1 - Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply

AU - Ytterberg, Steven R.

AU - Bhatt, Deepak L.

AU - Connell, Carol A.

PY - 2022/5/5

Y1 - 2022/5/5

UR - http://www.scopus.com/inward/record.url?scp=85129455835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129455835&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2202778

DO - 10.1056/NEJMc2202778

M3 - Letter

C2 - 35507493

AN - SCOPUS:85129455835

SN - 1533-4406

VL - 386

SP - 1768

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 18

ER -

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this